RxDoctor Payments Data

Mitchell Miller, MD

Family Medicine · Virginia Beach, VANPI 1902809437

Payments from drug & device makers

$187in general payments, 2019–2025

Across 4 payments — averaging $46.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Acadia Pharmaceuticals Inc$116
  • GSK$33
  • Novo Nordisk$19
  • Lilly USA, LLC$19

What the payments were for

  • Food & beverage$187100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Acadia Pharmaceuticals Inc1$116
GSK1$33
Novo Nordisk1$19
Lilly USA, LLC1$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$187 in reported general payments places this provider in the 40th percentile of 2,553 family medicine providers in Virginia.

See all family medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$408,223
Medicare patients
577
Services billed
4,510

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin37$58,335
EliquisApixaban55$50,826
JanuviaSitagliptin Phosphate23$36,872
XareltoRivaroxaban17$17,291
OzempicSemaglutide18$16,796
Losartan Potassium234$2,393
Atorvastatin Calcium268$2,360
Metoprolol Succinate169$2,216
SynthroidLevothyroxine Sodium48$1,731
Fenofibrate41$1,653
Simvastatin173$1,341
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide80$1,323
Levothyroxine Sodium175$1,315
Tamsulosin Hcl65$1,260
Rosuvastatin Calcium108$1,105

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$19$16,79618 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 2,553 family medicine providers in Virginia.

Other family medicine in Virginia Beach

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →